Advertisement

U.S. Markets closed

S&P Futures
5,893.75
-2.50(-0.04%)
Dow Futures
43,143.00
-34.00(-0.08%)
Nasdaq Futures
20,504.50
-15.00(-0.07%)
Russell 2000 Futures
2,251.30
-4.20(-0.19%)
Crude Oil
70.54
-0.02(-0.03%)
Gold
2,735.80
-3.10(-0.11%)

Inventiva S.A. (IVEVF)

OTC Markets OTCPK - OTC Markets OTCPK Delayed Price. Currency in USD

3.6400

0.0000

(0.00%)

At close: 04:00PM EDT

Trade prices are not sourced from all markets

All

GlobeNewswire
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
Daix (France), Long Island City (New York, United States), October 21, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), today announced that the results of the Phase 2, LEGEND, evaluating lanifibranor in combination
BioPharma Dive
Pfizer invests in molecular glue; Jazz, MeiraGTx shares rise on drug data
The pharma will work with Triana Biomedicines on molecular glue degraders. Elsewhere, Akeso raised $250 million and a MASH drug developer got a well-known board chair.